Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL30380649 | 0.95 | AGTR2 (0.71) | AGTR2AGTR1 | |
| Oxalic Acid SCHEMBL25295943 | 0.95 | AGTR2 (0.71) | AGTR2AGTR1 | |
| SCHEMBL25295942 | 0.90 | AGTR2 (0.67) | AGTR2AGTR1 | |
| SCHEMBL27590387 | 0.87 | AGTR2 (0.64) | AGTR2AGTR1 | |
| SCHEMBL708771 | 0.87 | AGTR2 (0.74) | AGTR2AGTR1 | |
| SCHEMBL26129430 | 0.87 | AGTR2 (0.59) | AGTR2AGTR1 | |
| SCHEMBL15524962 | 0.86 | AGTR2 (0.82) | AGTR2AGTR1 | |
| SCHEMBL26129020 | 0.86 | AGTR2 (0.55) | AGTR2AGTR1 | |
| SCHEMBL26128704 | 0.86 | AGTR2 (0.57) | AGTR2AGTR1 | |
| SCHEMBL30613503 | 0.86 | AGTR2 (0.55) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3876902-A1 | NEW COMPOSITION COMPRISING AMORPHOUS NANOPOROUS SILICA PARTICLES | Vicore Pharma AB (SE) | 2021-09-15 | — | — | EP | claimed |
| US-20230183223-A1 | PROCESS FOR THE SYNTHESIS OF N-BUTYLOXYCARBONYL-3-(4-IMIDAZOL-1- YLMETHYLPHENYL)-5-ISO-BUTYLTHIOPHENE-2-SULFONAMIDE | VICORE PHARMA AB (SE) | 2023-06-15 | — | — | US | disclosed |
| US-20230183223-A1 | PROCESS FOR THE SYNTHESIS OF N-BUTYLOXYCARBONYL-3-(4-IMIDAZOL-1- YLMETHYLPHENYL)-5-ISO-BUTYLTHIOPHENE-2-SULFONAMIDE | VICORE PHARMA AB (SE) | 2023-06-15 | — | — | US | disclosed |
| US-20230183223-A1 | PROCESS FOR THE SYNTHESIS OF N-BUTYLOXYCARBONYL-3-(4-IMIDAZOL-1- YLMETHYLPHENYL)-5-ISO-BUTYLTHIOPHENE-2-SULFONAMIDE | VICORE PHARMA AB (SE) | 2023-06-15 | — | — | US | disclosed |
| CN-115836066-A | Synthesis method of N-butoxycarbonyl-3- (4-imidazole-1-methyl phenyl) -5-isobutyl thiophene-2-sulfonamide | 维科尔药物公司 | 2023-03-21 | — | — | CN | disclosed |
| US-8124638-B2 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2012-02-28 | — | — | US | disclosed |
| CN-1529697-B | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB | 2010-09-22 | — | — | CN | disclosed |
| US-7652054-B2 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2010-01-26 | — | — | US | disclosed |
| US-20090326026-A1 | Tricyclic Compounds Useful as Angiotensin II Agonists | VICORE PHARMA AB | 2009-12-31 | — | — | US | disclosed |
| EP-1395566-B1 | TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| CN-1529697-A | Tricyclic compounds useful as angiotensin II agonists | ά�ƶ�ҩ�﹫˾ | 2004-09-15 | — | — | CN | disclosed |
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | AGTR1, AGTR2, NPY2R | AGTR2 2/4885AGTR1 1/4885 |
| US-20090326026-A1 | Tricyclic Compounds Useful as Angiotensin II Agonists | AGTR2, AGTR1, NPY4R | AGTR2 1/4885AGTR1 2/4885 |
| US-20230183223-A1 | PROCESS FOR THE SYNTHESIS OF N-BUTYLOXYCARBONYL-3-(4-IMIDAZOL-1- YLMETHYLPHENYL)-5-ISO-BUTYLTHIOPHENE-2-SULFONAMIDE | AGTR2, AGTR1, ACE2 | AGTR2 1/4885AGTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.